Table II.
Clinical characteristics of the hematologic recovery group and the unrecovered group at day +28.
| Characteristic | Recovery group | Unrecovered group | P-value |
|---|---|---|---|
| Gender | 1.0 | ||
| Male | 27 (69.23) | 15 (71.42) | |
| Female | 12 (30.76) | 6 (28.57) | |
| Age, years | 47 (23–72) | 42 (21–68) | 0.172 |
| ECOG score | 1 (0–3) | 2 (0–3) | 0.349 |
| Number of prior chemotherapies, times | 8 (3–26) | 9 (3–25) | 0.493 |
| Prior autologous HSCT | 0.278 | ||
| Yes | 1 (2.56) | 2 (9.52) | |
| No | 38 (97.43) | 19 (90.47) | |
| Bone marrow involvement | 0.114 | ||
| Yes | 3 (7.7) | 5 (23.8) | |
| No | 36 (92.3) | 16 (76.2) | |
| Targets of CAR-T cells | 0.599 | ||
| CD19 | 8 (20.5) | 2 (9.5) | |
| CD20 | 5 (12.8) | 2 (9.5) | |
| CD19-CD20 | 15 (38.5) | 8 (38.1) | |
| CD19-CD22 | 10 (25.6) | 9 (42.9) | |
| CD19-NK | 1 (2.6) | 0 (0) | |
| CRS | 0.796 | ||
| None | 12 (30.77) | 6 (28.57) | |
| Grade 1-2 | 25 (64.10) | 15 (71.43) | |
| Grade ≥3 | 2 (5.12) | 0 (0) | |
| NT | 0.193 | ||
| None | 34 (87.18) | 17 (80.95) | |
| Grade 1-2 | 5 (12.82) | 2 (9.52) | |
| Grade ≥3 | 0 (0) | 2 (9.52) | |
| Baseline ANC, ×109/l | 3.61 (0.61-7.01) | 1.77 (0.71-11.35) | 0.004 |
| Baseline hemoglobin, g/l | 119 (77–165) | 90 (51–147) | <0.001 |
| Baseline platelet count, ×109/l | 200 (54–447) | 151 (23–321) | 0.016 |
| Baseline CRP, mg/l | 7.2 (0.40-128.90) | 28.5 (1–200) | 0.022 |
| Baseline ferritin, ng/ml | 426 (20–3,323) | 774 (92.13–25,822) | 0.012 |
| Baseline IL-6, pg/l | 5.88 (1.50–57) | 22.25 (1.50–149.10) | 0.003 |
| Peak CRP, mg/l | 63.30 (1.30–200) | 91.3 (1.50–1,636) | 0.048 |
| Peak ferritin, ng/ml | 542.40 (25.12–7,000) | 1,396 (122.60–25,822) | 0.003 |
| Peak IL-6, pg/l | 21.35 (4.06–102) | 47.35 (5.02–1,453) | 0.040 |
Values are expressed as n (%) or the median (range). CRP, C-reactive protein; CAR-T, chimeric antigen receptor T-cell; ANC, absolute neutrophil count; CRS, cytokine release syndrome; NT, neurological toxicity; NK, natural killer; HSCT, hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group.